Francesca Barone, MD, PhD, on Viral Immunotherapy for Glioma, Prostate Cancer

Video

The chief scientific officer at Candel Therapeutics discussed progress in investigations with CAN-3110 and CAN-2409.

“The important thing is that we are focusing, especially with CAN-3110, on extremely difficult to treat tumors where classical immunotherapy has failed. And I really think that the ability of viral immunotherapy to add the ability of profoundly modifyingthe tumor microenvironment in situ is going to be key for this tumor to be converted from having a cold immunosuppressive microenvironment to hot tumors.”

Patients with recurrent high-grade glioma (rHGG) treated with a single intratumoral injection of Candel Therapeutics’ CAN-3110 (also known as rQNestin34.5v.2) tolerated the treatment well and had promising signals of efficacy and survival benefits according to new data from a phase 1/2 study (NCT03152318).

The data were presented by Francesca Barone, MD, PhD, chief scientific officer, Candel Therapeutics, at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, held May 16-20, in Los Angeles, California. CGTLive spoke with Barone to learn more about CAN-3110, also known as rQNestin34.5v.2, which is a Herpes simplex virus (HSV)-1 oncolytic viral immunotherapy.She discussed the unmet medical need with the current treatment landscape of recurrent high-grade glioma and potential advantages of CAN-3110.

Barone also discussed Candel’s lead candidate CAN-2409 (aglatimagene besadenovec), an adenoviral replication-defective engineered gene construct encoding the thymidine kinase gene derived from HSV. CAN-2409 is being investigated in a phase 3 trial (NCT02768363) in patients with prostate cancer.She outlined the progress of the trial and future investigations, as well as future research Candel is pursuing.

Click here to read more coverage of ASGCT 2023.

REFERENCE
Barone F, Ling A, Solomon IH, et al. Safety and survival outcomes in recurrent high-grade glioma patients treated with CAN-3110, a first-in-class ICP34.5 expressing oncolytic HSV1. News release. Presented at: ASGCT 2023 Annual Meeting; May 16-20; Los Angeles, California.
Related Videos
Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain
Salvador Rico, MD, PhD, on Informing Clinical Trials With Natural History Studies in Dravet
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
© 2024 MJH Life Sciences

All rights reserved.